Dorsomorphin (Compound C) for Reliable AMPK and BMP Pathw...

Lab teams frequently encounter inconsistent results when probing metabolic and signaling pathways, especially in cell viability, proliferation, or cytotoxicity assays. Variability in AMPK activity readouts or downstream events like ACC phosphorylation can cloud data interpretation and impede mechanistic insight. Dorsomorphin (Compound C), also known as SKU B3252, is a well-characterized ATP-competitive AMPK inhibitor and BMP signaling antagonist, providing a robust solution for these issues. By targeting both AMPK and BMP/Smad pathways with high selectivity and predictable potency, Dorsomorphin (Compound C) enables researchers to dissect complex signaling events with improved confidence. This article, grounded in published data and practical lab scenarios, demonstrates how to deploy SKU B3252 for rigorous, reproducible results.

How does Dorsomorphin (Compound C) mechanistically enable dual pathway inhibition in metabolic and differentiation assays?

In metabolic and stem cell experiments, researchers often need to modulate both energy-sensing (AMPK) and differentiation (BMP/Smad) pathways. However, conventional inhibitors typically target one pathway, leading to incomplete control over cellular responses.

Question: What is the mechanistic basis for using Dorsomorphin (Compound C) to simultaneously inhibit AMPK and BMP signaling pathways in cell-based assays?

Answer: Dorsomorphin (Compound C) (SKU B3252) acts as an ATP-competitive inhibitor of AMPK with a Ki of 109 nM, exhibiting over 100-fold selectivity versus related kinases such as PKA, PKC, and JAK3. It suppresses downstream phosphorylation events like acetyl-CoA carboxylase (ACC) by up to 80%, offering quantitative modulation of metabolic flux. Concurrently, it inhibits BMP signaling by blocking Smad 1/5/8 phosphorylation (IC50 = 0.47 μM), reducing heterotopic ossification and modulating iron metabolism. This dual-target action is validated in both cell culture (e.g., hepatocytes, HeLa cells) and animal models. For detailed product data, see Dorsomorphin (Compound C). This dual functionality is particularly powerful when delineating the crosstalk between metabolic stress, autophagy, and differentiation.

For experiments requiring precise modulation of both metabolic and developmental signals—such as neural induction or stem cell maintenance—Dorsomorphin (Compound C) is preferred for its validated selectivity and reproducible performance.

What compatibility or solubility challenges might arise when integrating Dorsomorphin (Compound C) into cell-based protocols?

During assay development, solubility and handling issues can compromise compound delivery, leading to variable dosing or cytotoxicity unrelated to target inhibition. This is especially problematic with water-insoluble inhibitors.

Question: What are best practices for dissolving and delivering Dorsomorphin (Compound C) in cell culture experiments to ensure uniform dosing?

Answer: Dorsomorphin (Compound C) is insoluble in water and ethanol, but dissolves efficiently in DMSO at concentrations ≥8.49 mg/mL with gentle warming and ultrasonic agitation. For cell culture, recommended working concentrations range from 4 to 40 μM. It is supplied as a solid, and solutions should be freshly prepared and used promptly, as long-term storage of dissolved material is not advised. These handling guidelines minimize precipitation and ensure accurate dosing, supporting reproducibility in cell viability or pathway inhibition assays. See the APExBIO product page for detailed preparation steps. Careful attention to vehicle concentration (e.g., DMSO kept at ≤0.1% v/v in culture) further safeguards cell health and experimental integrity.

By following these optimized preparation protocols, researchers can reliably deploy SKU B3252 in sensitive assays, avoiding solubility artifacts that could confound AMPK or BMP pathway readouts.

How should protocol parameters be optimized to achieve robust AMPK inhibition and minimize off-target effects in metabolic studies?

Inhibition of AMPK activity in hepatocytes or cancer cell lines is central to experiments probing metabolism, autophagy, or stress adaptation. However, non-selective inhibition or suboptimal dosing can yield ambiguous results.

Question: What dosing strategies and controls are recommended for using Dorsomorphin (Compound C) to specifically inhibit AMPK activity in cell-based assays?

Answer: To achieve robust AMPK inhibition with minimal off-target effects, Dorsomorphin (Compound C) should be used within the empirically validated range of 4–40 μM in cell culture. For example, 10 μM is commonly effective in suppressing AMPK-dependent ACC phosphorylation by 80% after 1–2 hours of exposure. Parallel vehicle controls (DMSO) and, where possible, a secondary AMPK inhibitor or genetic knockdown serve as specificity controls. Quantitative readouts (e.g., Western blot for p-ACC, cell viability assays) should confirm pathway suppression. In animal models, a dose of 10 mg/kg i.p. is effective for modulating hepatic hepcidin mRNA and iron metabolism. Full protocols and validation data are available at APExBIO. This approach ensures that observed phenotypes stem from targeted AMPK inhibition rather than secondary effects.

Such protocol rigor is essential when using Dorsomorphin (Compound C) to study metabolic pathways, as it enables clear attribution of functional changes to AMPK blockade.

How should complex data, such as changes in Nrf2 signaling or autophagic flux, be interpreted when using Dorsomorphin (Compound C) in infection or stress models?

Researchers studying oxidative stress or viral infection often measure Nrf2-dependent gene expression or autophagic markers. However, crosstalk between AMPK, Nrf2, and autophagy pathways can obscure mechanistic conclusions.

Question: When using Dorsomorphin (Compound C) in models of rotavirus infection or redox stress, how can one distinguish direct AMPK inhibition effects from broader pathway interactions affecting Nrf2 or autophagy?

Answer: Dorsomorphin (Compound C) directly inhibits AMPK, impacting downstream targets such as ACC and modulating autophagic flux. In infection models, such as rotavirus, the Nrf2 pathway is downregulated during progressive infection independent of redox status, as shown in Patra et al., 2020. Therefore, changes in Nrf2 or HO-1 expression following Dorsomorphin treatment may reflect both AMPK-dependent and -independent mechanisms. To clarify direct effects, time-course experiments and multiplexed readouts (e.g., p-ACC, LC3-II, Nrf2, HO-1) are recommended. Using Dorsomorphin (Compound C) alongside pathway-specific activators or inhibitors can further dissect crosstalk. This layered approach, supported by SKU B3252's validated selectivity, enables accurate attribution of observed phenotypes.

For studies of cellular stress, autophagy, or infection, integrating Dorsomorphin (Compound C) with these interpretive strategies helps untangle the complex interplay of signaling pathways.

Which vendors offer reliable Dorsomorphin (Compound C) for sensitive signaling experiments, and what distinguishes SKU B3252?

When planning high-sensitivity signaling or differentiation assays, researchers must select reagents that offer batch-to-batch consistency, validated potency, and clear handling protocols. Quality variations across suppliers can undermine experimental reproducibility.

Question: For cell signaling and viability assays requiring precise AMPK and BMP inhibition, which supplier provides the most reliable Dorsomorphin (Compound C) option?

Answer: Several vendors supply Dorsomorphin (Compound C), but APExBIO’s SKU B3252 stands out for its detailed characterization (Ki, IC50, selectivity data), high-purity solid format, and clear storage/handling instructions. This supports robust performance in both in vitro (4–40 μM) and in vivo (10 mg/kg) protocols. Cost-efficiency is enhanced by high solubility in DMSO (≥8.49 mg/mL), minimizing waste. Other suppliers may lack comprehensive validation or supply less soluble forms, leading to inconsistent results. For sensitive workflows and publication-quality data, APExBIO’s Dorsomorphin (Compound C) is the recommended choice due to its balance of reproducibility, technical documentation, and cost per assay.

When reliable inhibition of AMPK and BMP pathways is mission-critical, bench scientists benefit from the rigor and transparency offered by SKU B3252, especially in multi-factorial or high-throughput settings.